Cover Image
市場調查報告書

擴張型心肌病治療藥 (醛固酮拮抗劑,ACE抑制劑(血管張力素轉化酶抑制劑),血管收縮素II受體阻斷劑,β- 阻斷劑) 的全球市場:產業分析,開發平台分析,市場規模·佔有率·成長率·趨勢,未來預測 (2014∼2020年)

Dilated Cardiomyopathy Therapeutics Market (Aldosterone Antagonists, ACE Inhibitors, Angiotensin II Receptor Blockers and Beta-Blockers) - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

出版商 Transparency Market Research 商品編碼 328543
出版日期 內容資訊 英文 90 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
擴張型心肌病治療藥 (醛固酮拮抗劑,ACE抑制劑(血管張力素轉化酶抑制劑),血管收縮素II受體阻斷劑,β- 阻斷劑) 的全球市場:產業分析,開發平台分析,市場規模·佔有率·成長率·趨勢,未來預測 (2014∼2020年) Dilated Cardiomyopathy Therapeutics Market (Aldosterone Antagonists, ACE Inhibitors, Angiotensin II Receptor Blockers and Beta-Blockers) - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020
出版日期: 2015年03月20日 內容資訊: 英文 90 Pages
簡介

本報告提供全球·各地區的擴張型心肌病治療藥市場現況與未來展望相關分析,以全球整體的市場趨勢預測(以數量、金額為準,今後8年份)為首,提供您主要的推動及阻礙市場要素,及各各藥物分類的市場規模,開發平台(管線)候補藥的開發·臨床實驗情形,各地區市場趨勢預測,主要企業簡介,潛在的市場機會,市場誘因等的調查評估。

第1章 簡介

第2章 摘要整理

第3章 全球擴張型心肌病治療藥市場:概要

  • 市場定義·概要
    • 心肌病的分類
    • 推動市場要素
      • 由於心臟衰竭的發病量增加,擴大了有效治療藥的需求與推動市場成長
    • 阻礙市場要素
      • 擴張型心肌病的治療藥副作用限制了市場的成長
      • 由於無副作用的改良型醫療設備而限制了市場的成長
      • 由於有潛力的遺傳基因療法·肝細胞療法的登場,有可能降低治療藥市場的成長
    • 市場機會
      • 擴張型心肌病治療藥的一般化發展
  • 市場誘因分析:全球擴張型心肌病治療藥 (各地區)
  • 流行病學 (盛行率,要素,死亡率)
  • 擴張型心肌病相關流行病學研究
  • 原因及死亡率
  • 活動影響分析
  • 競爭情形:主要企業的情況
    • 主要企業的市場佔有率

第4章 全球擴張型心肌病治療市場:各藥物分類的區分

  • 簡介
    • 全球擴張型心肌病治療市場收益額:各藥物分類的明細 (總計9年份)
  • 醛固酮拮抗劑
  • 血管收縮素轉化酵素 (ACE) 抑制劑
  • 血管收縮素II受體阻斷劑 (ARB)
  • β- 阻斷劑

第5章 全球擴張型心肌病治療市場開發平台分析

第6章 全球擴張型心肌病治療藥市場:各地區的區分

  • 簡介
    • 全球擴張型心肌病治療市場收益額:各地區的明細 (總計9年份)
  • 北美
  • 歐洲
  • 亞太地區
  • 其他地區 (RoW)

第7章 建議

  • 肥厚性心肌病的擴張期
  • 遺傳基因操作

第8章 企業簡介

  • Array BioPharma, Inc.
    • 企業概要
    • 財務概要
    • 產品系列
    • 產業策略
    • 最近的發展趨勢
  • AstraZeneca plc
  • Celladon Corporation
  • GlaxoSmithKline plc
  • Janssen Pharmaceuticals, Inc.
  • Merck & Co., Inc
  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Vericel Corporation

圖表一覽

目錄

Dilated cardiomyopathy is an important cause of heart failure and is one of the leading indications for heart transplantation across the globe. It is characterized by the enlargement of ventricular chamber along with systolic dysfunction. Dilated cardiomyopathy can develop at any age but it is more common among people aged between 20 years and 60 years. According to American Society for Clinical Investigation about 25% - 50% of the total dilated cardiomyopathy cases are genetically caused, owing to mutation in genes encoding for cytoskeleton, contractile, or other proteins in myocardial cells.

The global dilated cardiomyopathy therapeutics market is studied in this report from three perspectives: by drug class, by pipelined products and by geography. Dilated cardiomyopathy therapeutics market by drug class encompasses aldosterone antagonists, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs) and beta-blockers. A detailed market analysis and forecast for each of these segments have been provided in this study, in terms of market revenue (USD million) for the period 2012 to 2020. The report also provides the compounded annual growth rate (CAGR %) for each of these segments for the forecast period from 2014 to 2020, considering 2012 and 2013 as base years. Geographic regions analyzed for this market include North America, Europe, Asia Pacific and Rest of the World. The North American market comprises the United States and Canada. The European market includes countries such as the U.K., Germany, Italy, and Spain that majorly contribute towards the growth of this region. Similarly, the Asia Pacific market primarily considers India, China, Japan, Singapore, and Australia, along with other smaller markets.

The market overview section of the report demonstrates the major factors determining the market dynamics such as drivers, restraints and opportunities that influence the current as well as future status of this industry. The market overview section of the report also includes qualitative and quantitative analysis of the competitive landscape covering market share analysis by key players.

The study also suggests a list of recommendations which would be useful for existing and future market players in decision making for business growth. Pipeline analysis (Phase I and Phase II) for dilated cardiomyopathy therapeutics market has also been covered in the report. The report concludes with the company profiles section, which illustrates key information about the major players in this market such as company overview, financial overview, product portfolio, business strategies and recent developments. Key players profiled in the report include Array BioPharma, Inc., AstraZeneca plc, Celladon Corporation, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novartis International AG, Pfizer, Inc., Teva Pharmaceutical Industries Ltd, and Vericel Corporation.

The global dilated cardiomyopathy therapeutics market is segmented into the following categories:

Dilated cardiomyopathy therapeutics market, by drug class

  • Aldosterone antagonists
  • Angiotensin-converting enzyme (ACE) inhibitors
  • Angiotensin II receptor blockers (ARBs)
  • Beta-blockers

Dilated cardiomyopathy therapeutics market, by pipeline drugs

  • ARRY-797
  • ixCELL-DCM
  • MYDICAR
  • OR-1
  • CAP-1002

Dilated cardiomyopathy therapeutics market, by geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World (RoW)

Table of Contents

Chapter 1 Introduction

  • 1.1 Report Description
  • 1.2 Market Segmentation
  • 1.3 Research Methodology
    • 1.3.1 Secondary Research
    • 1.3.2 Primary Research
  • 1.4 List of Abbreviations
  • 1.5 Assumptions and Stipulations

Chapter 2 Executive Summary

  • 2.1 Market Snapshot: Global Dilated Cardiomyopathy Therapeutics Market (2013 & 2020)
  • 2.2 Comparative Analysis: Global Dilated Cardiomyopathy Therapeutics Market Revenue, by Geography, 2013 & 2020 (Value %)

Chapter 3 Global Dilated Cardiomyopathy Therapeutics Market Overview

  • 3.1 Market Definition and Overview
    • 3.1.1 Classification of Cardiomyopathies
    • 3.1.2 Market Drivers
      • 3.1.2.1 Increasing number of heart failure cases worldwide will lead to rise in demand for effective medications, thereby driving market growth
    • 3.1.3 Market Restraints
      • 3.1.3.1 Side effects associated with DCM drugs could restrain market growth
      • 3.1.3.2 Enhanced relief from use of devices without any side effects will restrain the dilated cardiomyopathy drugs market
    • 3.1.4 Promising gene and stem cell therapies for DCM treatment may hamper the DCM drugs market growth
    • 3.1.5 Market Opportunities
    • 3.1.7 Increasing genericization of DCM drugs
  • 3.2 Market Attractiveness Analysis: Global Dilated Cardiomyopathy Therapeutics Market, by Geography, 2013
  • 3.3 Epidemiology (Prevalence, Cause, Mortality Rate)
  • 3.4 Epidemiology Studies on Dilated Cardiomyopathy
  • 3.5 Causes and Mortality
  • 3.6 Event Impact Analysis
  • 3.7 Competitive Landscape, by Key Players, 2013 (Value %)
    • 3.7.1 Market share by key players, 2013 (Value %)

Chapter 4 Global Dilated Cardiomyopathy Therapeutics Market, by Drug Class

  • 4.1 Introduction
    • 4.1.1 Global Dilated Cardiomyopathy Therapeutics Market Revenue, by Drug Class 2012 - 2020 (USD Million)
  • 4.2 Aldosterone Antagonists
    • 4.2.1 Global Aldosterone Antagonists Market Revenue, 2012 - 2020 (USD Million)
  • 4.3 Angiotensin-Converting Enzymes (ACE) Inhibitors
    • 4.3.1 Global Angiotensin-Converting Enzyme (ACE) Inhibitors Market Revenue, 2012 - 2020 (USD Million)
  • 4.4 Angiotensin II Receptor Blocker (ARBs)
    • 4.4.1 Global Angiotensin II Receptor Blockers (ARBs) Market Revenue, 2012 - 2020 (USD Million)
  • 4.5 Beta-Blockers
    • 4.5.1 Global Beta-Blockers Market Revenue, 2012 - 2020 (USD Million)

Chapter 5 Pipeline Analysis of Global Dilated Cardiomyopathy Therapeutics Market

  • 5.1 Pipeline Analysis
    • 5.1.1 Pipeline Analysis : Dilated Cardiomyopathy Therapeutics Market

Chapter 6 Global Dilated Cardiomyopathy Therapeutics Market, by Geography

  • 6.1 Introduction
    • 6.1.1 Global Dilated Cardiomyopathy Therapeutics Market Revenue, by Geography, 2012 - 2020 (USD Million)
  • 6.2 North America
    • 6.2.1 North America Dilated Cardiomyopathy Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • 6.3 Europe
    • 6.3.1 Europe Dilated Cardiomyopathy Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • 6.4 Asia Pacific
    • 6.4.1 Asia Pacific Dilated Cardiomyopathy Therapeutics market Revenue, 2012 - 2020 (USD Million)
  • 6.5 Rest of the World (RoW)
    • 6.5.1 Rest of the World Dilated Cardiomyopathy Therapeutics Market Revenue, 2012 - 2020 (USD Million)

Chapter 7 Recommendations

  • 7.1 Dilated phase of hypertrophic cardiomyopathy
  • 7.2 Genetic Intervention

Chapter 8 Company Profiles

  • 8.1 Array BioPharma, Inc.
    • 8.1.1 Company Overview
    • 8.1.2 Financial Overview
    • 8.1.3 Product Portfolio
    • 8.1.4 Business Strategies
    • 8.1.5 Recent Developments
  • 8.2 AstraZeneca plc
    • 8.2.1 Company Overview
    • 8.2.2 Financial Overview
    • 8.2.3 Product Portfolio
    • 8.2.4 Business Strategies
    • 8.2.5 Recent Developments
  • 8.3 Celladon Corporation
    • 8.3.1 Company Overview
    • 8.3.2 Financial Overview
    • 8.3.3 Product Portfolio
    • 8.3.4 Business Strategies
    • 8.3.5 Recent Developments
  • 8.4 GlaxoSmithKline plc
    • 8.4.1 Company Overview
    • 8.4.2 Financial Overview
    • 8.4.3 Product Portfolio
    • 8.4.4 Business Strategies
    • 8.4.5 Recent Developments
  • 8.5 Janssen Pharmaceuticals, Inc.
    • 8.5.1 Company Overview
    • 8.5.2 Financial Overview
    • 8.5.3 Product Portfolio
    • 8.5.4 Business Strategies
    • 8.5.5 Recent Developments
  • 8.6 Merck & Co., Inc.
    • 8.6.1 Company Overview
    • 8.6.2 Financial Overview
    • 8.6.3 Product Portfolio
    • 8.6.4 Business Strategies
    • 8.6.5 Recent Developments
  • 8.7 Novartis International AG
    • 8.7.1 Company Overview
    • 8.7.2 Financial Overview
    • 8.7.3 Product Portfolio
    • 8.7.4 Business Strategies
    • 8.7.5 Recent Developments
  • 8.8 Pfizer, Inc.
    • 8.8.1 Company Overview
    • 8.8.2 Financial Overview
    • 8.8.3 Product Portfolio
    • 8.8.4 Business Strategies
    • 8.8.5 Recent Developments
  • 8.9 Sanofi S.A.
    • 8.9.1 Company Overview
    • 8.9.2 Financial Overview
    • 8.9.3 Product Portfolio
    • 8.9.4 Business Strategies
    • 8.9.5 Recent Developments
  • 8.10 Teva Pharmaceutical Industries Ltd.
    • 8.10.1 Company Overview
    • 8.10.2 Financial Overview
    • 8.10.3 Product Portfolio
    • 8.10.4 Business Strategies
    • 8.10.5 Recent Developments
  • 8.11 Vericel Corporation
    • 8.11.1 Company Overview
    • 8.11.2 Financial Overview
    • 8.11.3 Product Portfolio
    • 8.11.4 Business Strategies
    • 8.11.5 Recent Developments

List of Figures

  • FIG. 1 Dilated Cardiomyopathy Therapeutics Market: Market Segmentation
  • FIG. 2 Global Dilated Cardiomyopathy Therapeutics Market, by Drug Class, 2013 (USD Million)
  • FIG. 3 Comparative Analysis: Global Dilated Cardiomyopathy Therapeutics Market Revenue, by Geography, 2013 & 2020 (Value %)
  • FIG. 4 Market Attractiveness Analysis: Global Dilated Cardiomyopathy Therapeutics Market, by Geography, 2013
  • FIG. 5 Market Share Analysis: Global Dilated Cardiomyopathy Therapeutics Market, by Key Players, 2013 (Value %)
  • FIG. 6 Global Aldosterone Antagonists Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 7 Global Angiotensin-Converting Enzyme (ACE) Inhibitors Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 8 Global Angiotensin II Receptor Blockers (ARBs) Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 9 Global Beta-Blockers Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 10 North America Dilated Cardiomyopathy Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 11 Europe Dilated Cardiomyopathy Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 12 Asia Pacific Dilated Cardiomyopathy Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 13 Rest of the World Dilated Cardiomyopathy Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 14 Array BioPharma, Inc.: Annual Revenue, 2012 - 2014 (USD Million)
  • FIG. 15 AstraZeneca plc: Annual Revenue, 2012 - 2014 (USD Million)
  • FIG. 16 GlaxoSmithKline plc: Annual Revenue, 2012 - 2014 (USD Million)
  • FIG. 17 Johnson & Johnson (Pharmaceutical Division): Annual Revenue 2011 - 2013 (USD Million)
  • FIG. 18 Merck & Co., Inc.: Annual Revenue, 2012 - 2014 (USD Million)
  • FIG. 19 Novartis International AG: Annual Revenue, 2012 - 2014 (USD Million)
  • FIG. 20 Pfizer, Inc.: Annual Revenue, 2012 - 2014 (USD Million)
  • FIG. 21 Sanofi S.A.: Annual Revenue, 2012 - 2014 (USD Million)
  • FIG. 22 Teva Pharmaceutical Industries Ltd.: Annual Revenue, 2012 - 2014 (USD Million)
  • FIG. 23 Vericel Corporation: Annual Revenue, 2011 - 2013 (USD Million)

List of Tables

  • TABLE 1 Market Snapshot: Global Dilated Cardiomyopathy Therapeutics Market (2013 & 2020)
  • TABLE 2 Classification of Cardiomyopathies
  • TABLE 3 Global Dilated Cardiomyopathy Therapeutics Market Revenue, by Drug Class, 2012 - 2020 (USD Million)
  • TABLE 4 Pipeline Analysis : Dilated Cardiomyopathy Therapeutics Market
  • TABLE 5 Global Dilated Cardiomyopathy Therapeutics Market Revenue, by Geography, 2012 - 2020 (USD Million)
Back to Top